JBM  Vol.7 No.7 , July 2019
The Application of Electrospray Tandem Mass Spectrometry for de novo Sequencing of Reduced Insulins
Abstract: Insulin, a blood glucose level mediator, is the mainstream therapeutic choice for diabetes patients. Since patent protection for many originator products is about to expire, manufacturers of follow-on insulin are determined to get their products authorized. According to regulations, a fundamental requirement for biosimilar compounds is that the chemical structure should be the same as that of the originator drug. Hence, the application of qualitative analysis for insulin products is essential during the production and development of biosimilars. In this study, the electrospray tandem MS/MS based de novo sequencing method was developed and validated by analyzing two insulin products with similar primary structures, namely recombinant human insulin and insulin aspart. The results indicated that the complete sequences of both reduced insulins are largely identifiable, although differentiation between leucine and isoleucine is not achieved. More importantly, the observed mass accuracy was substantial. The method can, therefore be applied to quality control and drug development.
Cite this paper: Gao, X. (2019) The Application of Electrospray Tandem Mass Spectrometry for de novo Sequencing of Reduced Insulins. Journal of Biosciences and Medicines, 7, 135-150. doi: 10.4236/jbm.2019.77011.

[1]   Lavalle-González, F.J. and Khatami, H. (2014) The Biosimilar Insulin Landscape: Current Developments. Postgraduate Medicine, 126, 81-92.

[2]   Pontes, C.E.C., Gouvea Barroso, W.B. and da Nóbrega Rito, P. (2019) Market for Biotechnology Drugs: Market Analysis of Insulin. Journal of Pharmaceutical Health Services Research, 10, 219-226.

[3]   Ladisch, M.R. and Kohlmann, K.L. (1992) Recombinant Human Insulin. Biotechnology Progress, 8, 469-478.

[4]   Heinemann, L. (2016) Biosimilar Insulin and Costs: What Can We Expect? Journal of Diabetes Science and Technology, 10, 457-462.

[5]   White, J. and Goldman, J. (2019) Biosimilar and Follow-on Insulin: The Ins, Outs, and Interchangeability. Journal of Pharmacy Technology, 35, 25-35.

[6]   Owens, D.R., Landgraf, W., Schmidt, A., Bretzel, R.G. and Kuhlmann, M.K. (2012) The Emergence of Biosimilar Insulin Preparations—A Cause for Concern? Diabetes Technology & Therapeutics, 14, 989-996.

[7]   Peters, A.L., Pollom, R.D., Zielonka, J.S., Carey, M.A. and Edelman, S.V. (2015) Biosimilars and New Insulin Versions. Endocrine Practice, 21, 1387-1394.

[8]   Frost, H. (2005) Antibody-Mediated Side Effects of Recombinant Proteins. Toxicology, 209, 155-160.

[9]   Malucchi, S. and Bertolotto, A. (2008) Clinical Aspects of Immunogenicity to Biopharmaceuticals. In: Weert, M., Møller, E.H., et al., Eds., Immunogenicity of Biopharmaceuticals. Biotechnology: Pharmaceutical Aspects, Springer, New York, 27-56.

[10]   Petrides, D., Sapidou, E. and Calandranis, J. (1995) Computer-Aided Process Analysis and Economic Evaluation for Biosynthetic Human Insulin Production—A Case Study. Biotechnology and Bioengineering, 48, 529-541.

[11]   Sahoo, N., Choudhury, K. and Manchikanti, P. (2009) Manufacturing of Biodrugs. BioDrugs, 23, 217-229.

[12]   Hjorth, C.F., Hubálek, F., Andersson, J., Poulsen, C., Otzen, D. and Naver, H. (2015) Purification and Identification of High Molecular Weight Products Formed During Storage of Neutral Formulation of Human Insulin. Pharmaceutical Research, 32, 2072-2085.

[13]   Rotenstein, L.S., Ran, N., Shivers, J.P., Yarchoan, M. and Close, K.L. (2012) Opportunities and Challenges for Biosimilars: What’s on the Horizon in the Global Insulin Market? Clinical Diabetes, 30, 138-150.

[14]   European Medicines Agency (2017) Biosimilars in the EU: Information Guide for Healthcare Professionals. European Medicines Agency and the European Commission.

[15]   Standing, K.G. (2003) Peptide and Protein De Novo Sequencing by Mass Spectrometry. Current Opinion in Structural Biology, 13, 595-601.

[16]   Thevis, M., Thomas, A. and Schänzer, W. (2008) Mass Spectrometric Determination of Insulins and Their Degradation Products in Sports Drug Testing. Mass Spectrometry Reviews, 27, 35-50.

[17]   Burns, J.A., Butler, J.C., Moran, J. and Whitesides, G.M. (1991) Selective Reduction of Disulfides by Tris (2-Carboxyethyl) Phosphine. The Journal of Organic Chemistry, 56, 2648-2650.

[18]   Cline, D.J., Redding, S.E., Brohawn, S.G., Psathas, J.N., Schneider, J.P. and Thorpe, C. (2004) New Water-Soluble Phosphines as Reductants of Peptide and Protein Disulfide Bonds: Reactivity and Membrane Permeability. Biochemistry, 43, 15195-15203.

[19]   Gray, W.R. (1993) Disulfide Structures of Highly Bridged Peptides: A New Strategy for Analysis. Protein Science, 2, 1732-1748.

[20]   Thevis, M., Thomas, A., Delahaut, P., Bosseloir, A. and Schänzer, W. (2005) Qualitative Determination of Synthetic Analogues of Insulin in Human Plasma by Immunoaffinity Purification and Liquid Chromatography-Tandem Mass Spectrometry for Doping Control Purposes. Analytical Chemistry, 77, 3579-3585.

[21]   Blackburn, M. (2013) Advances in the Quantitation of Therapeutic Insulin Analogues by LC-MS/MS. Bioanalysis, 5, 2933-2946.

[22]   Thevis, M., Thomas, A., Delahaut, P., Bosseloir, A. and Schänzer, W. (2006) Doping Control Analysis of Intact Rapid-Acting Insulin Analogues in Human Urine by Liquid Chromatography-Tandem Mass Spectrometry. Analytical Chemistry, 78, 1897-1903.

[23]   Thomas, A., Schänzer, W. and Thevis, M. (2014) Determination of Human Insulin and Its Analogues in Human Blood Using Liquid Chromatography Coupled to Ion Mobility Mass Spectrometry (LC-IM-MS). Drug Testing and Analysis, 6, 1125-1132.

[24]   Asbury, G.R. and Hill Jr., H.H. (2000) Evaluation of Ultrahigh Resolution Ion Mobility Spectrometry as an Analytical Separation Device in Chromatographic Terms. Journal of Microcolumn Separations, 12, 172-178.<172::AID-MCS7>3.0.CO;2-W